 Nevertheless, the combination of chemotherapy, T cells and high-dose IL-2 was shown to be effective even in patients who had previously failed high-dose IL-2 treatment.Rosenberg has pioneered the use of adoptive immunotherapy.Rosenberg received his B.A.